

Attorney Docket No.: 10017.200-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Schnorr et al.

Confirmation No: 5362

Serial No.: 09/784,554

Group Art Unit: 1651

Filed: February 16, 2001

Examiner: M. Rao

For: Family 44 Xyloglucanases

PATENT
FAX RECEIVED

JUL 03 2002

GROUP 1600

OFFICIAL

CERTIFICATE OF FACSIMILE TRANSMISSION

Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Response to Restriction Requirement

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner M. Rao, fax number (703) 308-4242.

Respectfully submitted,

Date: July 3, 2002



Elias J. Lambiris
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097

#13
L.P.

Attorney Docket No.: 10017.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Schnorr et al.

Confirmation No: 5362

Serial No.: 09/784,554

Group Art Unit: 1651

Filed: February 16, 2001

Examiner: M. Rao

For: Family 44 Xyloglucanases

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
Washington, DC 20231

Sir:

This paper is filed in response to the Office Action mailed June 18, 2002 that made a restriction requirement between the following groups:

Group I – claims 1-12, 19-20, 22-23 and 28 drawn to xyloglucanases and detergent compositions,

Group II – claim 24 drawn to polynucleotides encoding xyloglucanases, and

Group III – claim 29 drawn to process of washing a fabric.


In response to this requirement, Applicants hereby elect with traverse the invention of Group I. Applicants reserve the right to file continuing applications on the nonelected subject matter.

The basis for traverse is that there would not be a serious burden on the examiner if restriction were not required between Groups I and III. Moreover, Applicants submit that claim 1 links Groups I and III. Therefore, upon allowance of the linking claim, the restriction requirement as to the linked inventions should be withdrawn and all claims within the linked inventions should be examined in the instant application.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this response or application.

Respectfully submitted,

Date: July 3, 2002


Elias J. Lambiris, Reg. No. 33,728
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097